PASG News and Press, Passage Bio Inc. From 01/04/21

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient in first quarter 2021 PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on...

- Company invests to build in-house capabilities to support advancement of pipeline - - In combination with dedicated CGMP suite at Catalent, the new laboratory creates foundation for integrated AAV gene therapy manufacturing - PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) ...

The U.K regulatory authority has signed off Passage Bio's (PASG) trial application for global Phase 1/2 study evaluating the company's lead gene therapy, PBGM01, for the treatment of GM1 gangliosidosis (GM1). This is the first regulatory authorization for the global PBGM01 trial program,...

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - P atient enrollment in UK clinical study site expected to start in the second quarter of 2021 - PHILADELPHIA, ...

PHILADELPHIA and SOMERSET, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, and Catalent, the leading global provider of advanced d...

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., chief executive officer of Passage ...

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today commends the newly published research of the University of Pennsylva...

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investo...

Passage Bio, Inc. (PASG) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Zoe Mita - IR, Stern Investor Relations, Inc. Bruce Goldsmith - President and Chief Executive Officer Rich Morris - Chief Financial Officer Jill Quigley - Chief Operating Officer Gary R...

Passage Bio (PASG): Q3 GAAP EPS of -$0.63 beats by $0.13.Cash, cash equivalents and marketable securities of $335.7MPress Release For further details see: Passage Bio EPS beats by $0.13